Moreno-Martínez A, Mensa J, Martínez J A, Marco F, Vila J, Almela M, García San Miguel J, Soriano E
Servicios de Enfermedades Infecciosas y Microbiología, Hospital Clínic i Provincial, Barcelona.
Med Clin (Barc). 1998 Oct 31;111(14):521-4.
Community-acquired non-complicated acute pyelonephritis (APN) is a frequent, occasionally serious infection (around 20% of the cases are bacteremic) that usually requires hospital admission. The third generation oral cephalosporins which are active against more than 95% of E. coli strains should allow the outpatient management of these patients.
To evaluate the bacteriological and clinical efficacy of oral cefixime in comparison to amoxicilin plus netilcilin in the treatment of APN.
Patients older than 18 years affected by APN were included in a fourteen month prospective study. According to a random numbers chart, the patients received cefixime (400 mg/24 h in a single daily dose for 12 days) or amoxicilin (1 g/8 h per os) plus netilmicin (4 mg/kg/24 h in a single intramuscular daily dose) during five days followed by 7 days of an oral treatment chosen according to the susceptibility pattern of isolated microorganism.
Sixty-one patients received cefixime and 65 amoxicillin plus retilmicin. There were no significant differences between both groups of patients. Thirty-two patients presented bacteremia (25.4%). The mean (SD) eak and trough concentrations of netilmicin were 11.4 (2.8) mg/l and 0.38 (0.4) mg/l, respectively. Clinical response was favorable in 97% of patients treated with cefixime and in 98% of those treated with amoxicilin plus netilmicin (p = NS). The infection recurred in 10 out of 59 patients (16.9%) in the cefixime arm of the study and in 9 out of 64 patients (14%) treated with amoxicillin plus netilmicin (p = NS). Tolerance to the study drugs was good in both arms of the study, and renal function remained normal.
Cefixime seems to be an acceptable alternative to the regimens containing an aminopenicillin and an aminoglycoside for the treatment of community-acquired non-complicated APN.
社区获得性非复杂性急性肾盂肾炎(APN)是一种常见的感染,偶尔会较为严重(约20%的病例有菌血症),通常需要住院治疗。对超过95%的大肠杆菌菌株有效的第三代口服头孢菌素应能让这些患者在门诊接受治疗。
评估口服头孢克肟与阿莫西林加奈替米星相比在治疗APN中的细菌学和临床疗效。
18岁以上患APN的患者被纳入一项为期14个月的前瞻性研究。根据随机数字表,患者接受头孢克肟(每日单次剂量400mg/24h,共12天)或阿莫西林(口服1g/8h)加奈替米星(每日单次肌内注射剂量4mg/kg/24h)治疗5天,随后根据分离出的微生物的药敏模式进行7天的口服治疗。
61例患者接受了头孢克肟治疗,65例患者接受了阿莫西林加奈替米星治疗。两组患者之间无显著差异。32例患者出现菌血症(25.4%)。奈替米星的平均(标准差)峰浓度和谷浓度分别为11.4(2.8)mg/l和0.38(0.4)mg/l。接受头孢克肟治疗的患者中97%临床反应良好,接受阿莫西林加奈替米星治疗的患者中98%临床反应良好(p=无统计学意义)。在研究的头孢克肟组中,59例患者中有10例(16.9%)感染复发,在接受阿莫西林加奈替米星治疗的64例患者中有9例(14%)感染复发(p=无统计学意义)。研究的两组对研究药物的耐受性均良好,肾功能保持正常。
对于社区获得性非复杂性APN的治疗,头孢克肟似乎是含氨基青霉素和氨基糖苷类方案的可接受替代方案。